Xiaozhen Liu

1.3k total citations
56 papers, 874 citations indexed

About

Xiaozhen Liu is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Xiaozhen Liu has authored 56 papers receiving a total of 874 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 22 papers in Oncology and 21 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Xiaozhen Liu's work include Lung Cancer Treatments and Mutations (11 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Lung Cancer Research Studies (6 papers). Xiaozhen Liu is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Lung Cancer Research Studies (6 papers). Xiaozhen Liu collaborates with scholars based in China, United States and Germany. Xiaozhen Liu's co-authors include Sha Zhao, Yijun Jia, Limin Zhang, Tao Jiang, Xuefei Li, Chao Zhao, Jinpeng Shi, Shengxiang Ren, Chunxia Su and Caicun Zhou and has published in prestigious journals such as Cancer, Scientific Reports and International Journal of Cancer.

In The Last Decade

Xiaozhen Liu

52 papers receiving 862 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiaozhen Liu China 17 415 362 358 174 122 56 874
Yuekun Wang China 16 223 0.5× 315 0.9× 216 0.6× 155 0.9× 120 1.0× 37 770
Gina M. Sizemore United States 13 300 0.7× 472 1.3× 120 0.3× 204 1.2× 91 0.7× 27 792
Carmen Dominguez‐Brauer United States 11 238 0.6× 561 1.5× 104 0.3× 112 0.6× 82 0.7× 11 825
Yu Lin China 13 329 0.8× 357 1.0× 117 0.3× 211 1.2× 233 1.9× 26 813
André Steven Germany 13 239 0.6× 387 1.1× 91 0.3× 147 0.8× 284 2.3× 19 797
Peter Hovland United States 11 191 0.5× 404 1.1× 111 0.3× 82 0.5× 70 0.6× 16 773
Lon D. Ridgway United States 10 507 1.2× 602 1.7× 128 0.4× 309 1.8× 51 0.4× 11 1.0k
Nathaniel Weygant United States 26 753 1.8× 651 1.8× 186 0.5× 358 2.1× 214 1.8× 55 1.5k
Xuan Xie China 16 170 0.4× 348 1.0× 143 0.4× 142 0.8× 42 0.3× 45 772

Countries citing papers authored by Xiaozhen Liu

Since Specialization
Citations

This map shows the geographic impact of Xiaozhen Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaozhen Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaozhen Liu more than expected).

Fields of papers citing papers by Xiaozhen Liu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaozhen Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaozhen Liu. The network helps show where Xiaozhen Liu may publish in the future.

Co-authorship network of co-authors of Xiaozhen Liu

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaozhen Liu. A scholar is included among the top collaborators of Xiaozhen Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaozhen Liu. Xiaozhen Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Liu, Xiaozhen, Shiqi Mao, Chuchu Shao, et al.. (2025). BIRC5 expression correlates with immunosuppressive phenotype and predicts inferior response to immunotherapy in lung adenocarcinoma. Journal of Thoracic Disease. 17(8). 5921–5935.
3.
4.
5.
Tang, Hongchao, Danhong Wang, Da Qian, et al.. (2024). Xihuang pill suppresses breast cancer malignancy by inhibiting TGF-β signaling and acquires chemotherapy benefits. Journal of Ethnopharmacology. 337(Pt 3). 119000–119000. 4 indexed citations
6.
Qian, Da, Jie Qiu, Yadan Xu, et al.. (2024). Whole transcriptome sequencing indicated the Anti-tumor immunity of NLRP3 in breast cancer. Genomics. 116(5). 110930–110930.
7.
Han, Ruoshuang, Haoyue Guo, Jinpeng Shi, et al.. (2024). Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer. BMC Medicine. 22(1). 174–174. 11 indexed citations
8.
Song, Feifeng, Zhentao Zhang, Lixiang Zhao, et al.. (2024). Zebrafish patient-derived xenograft system for predicting carboplatin resistance and metastasis of ovarian cancer. Drug Resistance Updates. 78. 101162–101162. 2 indexed citations
9.
Yang, Kun, et al.. (2024). Knowledge, attitude, and practice toward ultrasound screening for breast cancer among women. Frontiers in Public Health. 12. 1309797–1309797. 3 indexed citations
10.
Qiu, Jie, et al.. (2023). Pan-cancer Analysis Identifies AIMP2 as a Potential Biomarker forBreast Cancer. Current Genomics. 24(5). 307–329. 7 indexed citations
11.
Li, Jiacheng, Xiaozhen Liu, Lin Chen, et al.. (2023). Isopimaric acid, an ion channel regulator, regulates calcium and oxidative phosphorylation pathways to inhibit breast cancer proliferation and metastasis. Toxicology and Applied Pharmacology. 462. 116415–116415. 8 indexed citations
12.
Han, Ruoshuang, Yijun Jia, Xuefei Li, et al.. (2021). Concurrent use of metformin enhances the efficacy of EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer—an option for overcoming EGFR-TKI resistance. Translational Lung Cancer Research. 10(3). 1277–1291. 16 indexed citations
13.
Li, Lejun, Hongping Li, Yonghong Tian, et al.. (2020). Differential microRNAs expression in seminal plasma of normospermic patients with different sperm DNA fragmentation indexes. Reproductive Toxicology. 94. 8–12. 10 indexed citations
14.
Cao, Lu, et al.. (2018). Clinical significance of PDEF factor expression and its relation to androgen receptor in ER− breast cancer. Histopathology. 73(5). 819–831. 9 indexed citations
15.
Cao, Lu, Cong Xu, Xiaozhen Liu, et al.. (2018). AR–PDEF pathway promotes tumour proliferation and upregulates MYC-mediated gene transcription by promoting MAD1 degradation in ER-negative breast cancer. Molecular Cancer. 17(1). 136–136. 18 indexed citations
16.
17.
Liu, Xiaozhen, Junjun Liu, Jian Liu, et al.. (2018). The importance of EGFR as a biomarker in molecular apocrine breast cancer. Human Pathology. 77. 1–10. 11 indexed citations
18.
Zhang, Limin, Tao Jiang, Chao Zhao, et al.. (2016). Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement. Oncotarget. 7(46). 75145–75154. 44 indexed citations
19.
Zhao, Sha, Tao Jiang, Limin Zhang, et al.. (2016). Clinicopathological and prognostic significance of regulatory T cells in patients with non-small cell lung cancer: A systematic review with meta-analysis. Oncotarget. 7(24). 36065–36073. 39 indexed citations
20.
Zhang, Hanyao, et al.. (2006). Genetic Diversity among flue-cured Tobacco (Nicotiana tabacum L.) Revealed by Amplified Fragment Length Polymorphism. Botanical studies. 47(3). 223–229. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yuekun Wang Breakdown of academic impact, for papers by Gina M. Sizemore Breakdown of academic impact, for papers by Carmen Dominguez‐Brauer Breakdown of academic impact, for papers by Yu Lin Breakdown of academic impact, for papers by André Steven Breakdown of academic impact, for papers by Peter Hovland Breakdown of academic impact, for papers by Lon D. Ridgway Breakdown of academic impact, for papers by Nathaniel Weygant Breakdown of academic impact, for papers by Xuan Xie
Rankless by CCL
2026